Navigation Links
US Senate Passes Stem Cell Research Bill

The US Senate has passed a bill that aims to loosen President George Bush's restrictions on human embryonic stem cell research for the second time// in nine months, but has once again fallen short of the 67 votes needed to override a promised veto, media reports said.

The Senate voted 63 to 34 to pass the Stem Cell Research Enhancement Act, which would allow federally funded studies of stem cells isolated from embryos slated for destruction at fertility clinics, the Washington Post reported Wednesday.

The vote capped 20 hours of often passionate debate, with proponents focusing on the cells' potential to help treat a wide range of diseases and opponents decrying the fact that human embryos must be destroyed to retrieve them.

With the House having passed a similar bill in January, the two chambers are now set to hammer out compromise wording and send the legislation to Bush. But the White House Tuesday set the stage for a new Bush veto, saying it was unthinkable that public tax money should be used to destroy human embryos.

Bush used his power of veto for the first time in his presidency to slap down a similar text passed in Congress last year, when it was then controlled by his Republican party.

However, proponents are relishing the fact that they will have the opportunity to rebuke the president by overriding that veto this time.

Although the House majority favouring the legislation is 15 votes larger this year than that in 2005, it is still dozens short of the two-thirds needed for an override.

In that case, Bush's veto pen will prevail and the situation will revert to what it has been since Aug 9, 2001 -- when Bush, in his first major televised address to the nation, declared that federal funds could only be used to study stem cells derived from embryos already destroyed by that date.

Source-IANS/B
'"/>




Page: 1

Related medicine news :

1. Senate assures ban on smoking
2. US Senate Votes against Testing of Pesticide on Humans
3. US Senate Approves Embryo-research Plan Despite Presidents Refusal
4. Senate Committee Approves Telemedicine Mental Health Bill
5. Organ Donation Crusader Passes Away
6. A Mother Passes On A Rare, Terminal Brain Disease To Her Three Children
7. Renowned Doctor Passes Away
8. Founder of Enron, Ken Lay Passes Away
9. Maoist Leader-Turned Social Activist Passes Away
10. Jeff Getty, AIDS Activist, Passes Away
11. WHO Passes Rotavirus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Senate Passes Stem Cell Research Bill

(Date:5/16/2008)...wswire-USNewswire/- "Huh, what did you,say?" is a ...larly our,children. More than 30 million Americans...ring loss and the numbers are growing at a dramati...ren have some form of hearing,loss. An effort to b...oblem,is what led Kathlyn Maguire, who has profoun...
(Date:5/16/2008)... May 19 at 10:15 a.m. Eastern Time, VANCOUVER, Ma...Corporation (TSX: RBM, OTCBB: RPBIF) today announc...scheduled to present at the Rodman & Renshaw,5th A...9th at 10:15 a.m.,EDT., A live web cast of the pr...site at, http://www.responsebio.com/newsroom_event...
(Date:5/16/2008)...unemployed politicians - and economists, ORLANDO...nearly all,voters place health care at the top of ...ral budgetary crunch means none of the health care... candidates is likely to become,law anytime soon, ...., Jousting with Princeton University Health care...
(Date:5/16/2008)... Huntsworth plc (LSE: HNT), "the Group",a leading...munications,group headquartered in London, release...e Group,s performance in the first quarter 2008 (t...t follows below., 15 May 2008, ...nterim Management Statement, Record ne...
Breaking Medicine News(10 mins):Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4
... federal parliamentary committee that was formed t...de, and had heard the demand for breast reduction/...em of prioritising patients. This meant that a wom...anting her breasts reduced has to wait just as lon...
...frican heads of state plan to meet this week in Ab...eversing the spread of infectious diseases// like ...he leaders had set a target of increasing health s...ional budgets in order to accelerate a continental...
...hildren who reside close to major roads carry a po... children who stay even slightly away, reveals a s...ironmental Health Perspectives. The study found t...(about 82 yards) of a major road had a 50 percent ...
...aternal food choices can play a crucial role in de...ights a new study // conducted by researchers at B...nd Boston Medical Center (BMC). The impact of this...loping and underdeveloped countries where access t...
Other Medicine News:Health News:Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery 2Health News:Review of Reversal of Spread of Diseases in Africa 2Health News:Asthma Risk Pronounced In Children Living Close to Traffic Ridden Roads 2
(Date:5/15/2008)...rstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) toda...inical,trial of its novel androgen receptor antago...tation at the 44th American Society of Clinical On...on title: New Targeted Strategies for Patients wit...June 2 at 11:30 a.m. Central Time Abstract title:...
(Date:5/15/2008)... reflects depth and breadth of, collaboration wit...s for diverse forms of canc...ta(R), the leading IV, bisphosphonate, on relapse ...- Four oral sessions to feature RAD001, first oral...ng first results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...e, May 15 /- Cerenis,Therapeutics SA ...,developing HDL-related compounds for the treatmen...announced that it has completed a Phase I,clinical...uct candidates.,CER-002 is a peroxisome proliferat...t in development for the treatment of cardiovascul...
(Date:5/15/2008)...Antiplatelet Therapy that, Combined, with Aspirin,...ix/Iscover and Aspirin, According to a New Rep...15 /- Decision Resources, one of the,...armaceutical and,healthcare issues, finds that Dai... in patient compared to Sanofi-Aventis/Bristol Mye...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Hybrid materials 3A Exciting interdisciplinary field offering future solutions for industry 3777 1Hybrid materials 3A Exciting interdisciplinary field offering future solutions for industry 3777 2Vaccine Could One Day Control High Blood Pressure 13746 1Vaccine Could One Day Control High Blood Pressure 13746 2Vaccine Could One Day Control High Blood Pressure 13746 3FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX 28TM 29 13742 1FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX 28TM 29 13742 2FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX 28TM 29 13742 3Arizona Senate Pushes for Smoking Cessation Treatments for State Medicaid Beneficiaries 13738 1Arizona Senate Pushes for Smoking Cessation Treatments for State Medicaid Beneficiaries 13738 2
Seldin 23, excellent for flap retraction.
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm).
Medicine Products: